The FDA and EMA regulatory policies for pediatric drugs are introduced from the aspects of regulatory policy establishment, implementation scope of pediatric study plan, review time limit and application requirements, some suggestions are put forward to further improve pediatric drug regulation in China. In combination with the revision of “Regulations for the Implementation of the Drug Administration Law” and the current situation of drug review resources, some recommendations are listed as follows: further improving the legal and regulatory system for the supervision of pediatric drugs, formulating relevant working procedures for pediatric study plan in line with the actual drug review condition in China, further supplementing the technical guidelines for pediatric drugs, guiding and standardizing research and development process for pediatric drugs of manufacturing enterprises, promoting pediatric drug innovative process, and effectively solving the unmet clinical needs of pediatric population in China.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |